Marksans Pharma Limited (BOM:524404)
India · Delayed Price · Currency is INR 325.30
+0.95 (0.29%)
At close: Oct 7, 2026
Marksans Pharma Ratios and Metrics
Market cap in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 6, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 147,437 | 71,097 | 100,815 | 68,836 | 31,903 | 18,627 | |
Market Cap Growth | 95.37% | -29.48% | 46.46% | 115.77% | 71.27% | -8.89% |
Enterprise Value | 141,257 | 68,000 | 96,315 | 63,549 | 29,746 | 16,052 |
Last Close Price | 324.35 | 156.72 | 220.96 | 150.30 | 69.52 | 44.70 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 6, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 28.45 | 17.01 | 26.49 | 21.94 | 11.98 | 9.97 |
PS Ratio | 4.63 | 2.41 | 3.84 | 3.16 | 1.72 | 1.25 |
PB Ratio | 4.82 | 2.33 | 4.05 | 3.30 | 1.81 | 1.52 |
P/TBV Ratio | 5.14 | 2.49 | 4.28 | 3.51 | 1.95 | 1.67 |
P/FCF Ratio | 44.87 | 21.70 | 298.76 | 319.14 | 17.36 | 35.20 |
P/OCF Ratio | 32.09 | 15.52 | 48.78 | 29.88 | 13.44 | 18.77 |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 6, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 4.44 | 2.30 | 3.67 | 2.92 | 1.61 | 1.08 |
EV/EBITDA Ratio | 19.74 | 12.05 | 19.06 | 14.65 | 9.29 | 6.68 |
EV/EBIT Ratio | 22.95 | 13.53 | 21.44 | 16.54 | 10.34 | 7.50 |
EV/FCF Ratio | 42.99 | 20.76 | 285.42 | 294.63 | 16.19 | 30.33 |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 6, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | 0.11 | 0.11 | 0.13 | 0.12 | 0.07 | 0.09 |
Debt / EBITDA Ratio | 0.48 | 0.57 | 0.60 | 0.53 | 0.36 | 0.43 |
Debt / FCF Ratio | - | 1.05 | 9.54 | 11.32 | 0.67 | 2.09 |
Net Debt / Equity Ratio | -0.21 | -0.21 | -0.15 | -0.22 | -0.34 | -0.19 |
Net Debt / EBITDA Ratio | -0.96 | -1.15 | -0.76 | -1.05 | -1.85 | -0.98 |
Net Debt / FCF Ratio | - | -1.98 | -11.38 | -21.20 | -3.23 | -4.46 |
Asset Turnover | - | 0.83 | 0.89 | 0.89 | 0.97 | 1.04 |
Inventory Turnover | - | 1.47 | 1.64 | 1.95 | 2.07 | 1.76 |
Quick Ratio | - | 3.13 | 2.64 | 2.99 | 3.34 | 2.09 |
Current Ratio | - | 5.17 | 4.62 | 4.78 | 4.91 | 3.37 |
Return on Equity (ROE) | - | 15.16% | 16.73% | 16.35% | 17.76% | 17.55% |
Return on Assets (ROA) | - | 8.85% | 9.49% | 9.86% | 9.39% | 9.33% |
Return on Invested Capital (ROIC) | 19.26% | 16.70% | 18.27% | 20.40% | 20.94% | 18.80% |
Return on Capital Employed (ROCE) | - | 15.10% | 16.30% | 16.80% | 15.60% | 16.70% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 6, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | 3.52% | 5.88% | 3.77% | 4.56% | 8.35% | 10.03% |
FCF Yield | 2.23% | 4.61% | 0.34% | 0.31% | 5.76% | 2.84% |
Dividend Yield | 0.28% | 0.57% | 0.36% | 0.40% | 0.72% | 0.56% |
Payout Ratio | - | 8.67% | 7.14% | 7.22% | 3.82% | 5.67% |
Buyback Yield / Dilution | -0.22% | - | - | -9.09% | -1.49% | - |
Total Shareholder Return | 0.06% | 0.57% | 0.36% | -8.69% | -0.77% | 0.56% |